Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis

Alessandro Salvalaggio; Daniele Coraci; Laura Obici; Mario Cacciavillani; Marco Luigetti; Anna Mazzeo; Francesca Pastorelli; Marina Grandis; Tiziana Cavallaro; Giulia Bisogni; Alessandro Lozza; Chiara Gemelli; Luca Gentile; Massimo Russo; Mario Ermani; Gian Maria Fabrizi; Rosaria Plasmati; Federica De Napoli; Marta Campagnolo; Francesca Castellani; Fabrizio Salvi; Silvia Fenu; Grazia Devigili; Davide Pareyson; Roberto Gasparotti; Claudio Rapezzi; Carlo Martinoli; Luca Padua; Chiara Briani

doi:10.1007/s00415-021-10754-9

Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis

Alessandro Salvalaggio, Daniele Coraci, Laura Obici, Mario Cacciavillani, Marco Luigetti, Anna Mazzeo, Francesca Pastorelli, Marina Grandis, Tiziana Cavallaro, Giulia Bisogni, Alessandro Lozza, Chiara Gemelli, Luca Gentile, Massimo Russo, Mario Ermani, Gian Maria Fabrizi, Rosaria Plasmati, Federica De Napoli, Marta Campagnolo, Francesca CastellaniFabrizio Salvi, Silvia Fenu, Grazia Devigili, Davide Pareyson, Roberto Gasparotti, Claudio Rapezzi, Carlo Martinoli, Luca Padua, Chiara Briani

Research output: Contribution to journal › Article › peer-review

Abstract

Axonal polyneuropathy is the main feature of hereditary transthyretin amyloidosis (ATTRv). Nerve morphological abnormalities have been reported, but longitudinal changes have never been assessed. We performed a prospective widespread nerve ultrasound evaluation and nerve cross-sectional area (CSA) was compared with baseline data in both ATTRv patients and pre-symptomatic carriers. Thirty-eight subjects were evaluated (mean follow-up 17.1 months), among them 21 had polyneuropathy while 17 were pre-symptomatic carriers. CSA significantly increased at brachial plexus in both groups (p = 0.008 and p = 0.012) pointing to progressive brachial plexus enlargement as a longitudinal biomarker of both disease progression and disease occurrence in pre-symptomatic carriers.

Original language	English
Journal	Journal of Neurology
DOIs	https://doi.org/10.1007/s00415-021-10754-9
Publication status	Accepted/In press - 2021

Keywords

Amyloidosis
Brachial plexus
Peripheral nerves
Transthyretin
Ultrasound

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1007/s00415-021-10754-9

Cite this

Salvalaggio, A., Coraci, D., Obici, L., Cacciavillani, M., Luigetti, M., Mazzeo, A., Pastorelli, F., Grandis, M., Cavallaro, T., Bisogni, G., Lozza, A., Gemelli, C., Gentile, L., Russo, M., Ermani, M., Fabrizi, G. M., Plasmati, R., De Napoli, F., Campagnolo, M., ... Briani, C. (Accepted/In press). Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis. Journal of Neurology. https://doi.org/10.1007/s00415-021-10754-9

Salvalaggio, A, Coraci, D, Obici, L, Cacciavillani, M, Luigetti, M, Mazzeo, A, Pastorelli, F, Grandis, M, Cavallaro, T, Bisogni, G, Lozza, A, Gemelli, C, Gentile, L, Russo, M, Ermani, M, Fabrizi, GM, Plasmati, R, De Napoli, F, Campagnolo, M, Castellani, F, Salvi, F , Fenu, S , Devigili, G , Pareyson, D, Gasparotti, R, Rapezzi, C, Martinoli, C, Padua, L & Briani, C 2021, 'Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis', Journal of Neurology. https://doi.org/10.1007/s00415-021-10754-9

@article{f315dc9203254e079e76ce221b1bd046,

title = "Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis",

abstract = "Axonal polyneuropathy is the main feature of hereditary transthyretin amyloidosis (ATTRv). Nerve morphological abnormalities have been reported, but longitudinal changes have never been assessed. We performed a prospective widespread nerve ultrasound evaluation and nerve cross-sectional area (CSA) was compared with baseline data in both ATTRv patients and pre-symptomatic carriers. Thirty-eight subjects were evaluated (mean follow-up 17.1 months), among them 21 had polyneuropathy while 17 were pre-symptomatic carriers. CSA significantly increased at brachial plexus in both groups (p = 0.008 and p = 0.012) pointing to progressive brachial plexus enlargement as a longitudinal biomarker of both disease progression and disease occurrence in pre-symptomatic carriers.",

keywords = "Amyloidosis, Brachial plexus, Peripheral nerves, Transthyretin, Ultrasound",

author = "Alessandro Salvalaggio and Daniele Coraci and Laura Obici and Mario Cacciavillani and Marco Luigetti and Anna Mazzeo and Francesca Pastorelli and Marina Grandis and Tiziana Cavallaro and Giulia Bisogni and Alessandro Lozza and Chiara Gemelli and Luca Gentile and Massimo Russo and Mario Ermani and Fabrizi, {Gian Maria} and Rosaria Plasmati and {De Napoli}, Federica and Marta Campagnolo and Francesca Castellani and Fabrizio Salvi and Silvia Fenu and Grazia Devigili and Davide Pareyson and Roberto Gasparotti and Claudio Rapezzi and Carlo Martinoli and Luca Padua and Chiara Briani",

note = "Funding Information: Alessandro Salvalaggio reports travel grants from Akcea, Alnylam and Pfizer and consulting honoraria from Alnylam. Laura Obici reports speaker and consulting honoraria from Akcea, Alnylam and Pfizer. Marco Luigetti reports financial grants (honoraria and speaking) from Akcea, Alnylam and Pfizer, and travel grants from Pfizer, Kedrion and Grifols. Gulia Bisogni reports financial grants (honoraria and speaking) from Alnylam and travel grants from Pfizer and Grifols. Gian Maria Fabrizi reports consulting honoraria from Akcea and Alnylam, and travel grants from Kedrion and Alnylam. Chiara Gemelli reports travel grants from Akcea and Pfizer. Carlo Martinoli reports financial relationships (consultant, speaker fees, adv board) with Pfizer, Novartis, Sobi, Takeda and Novonordisk. Chiara Briani reports speaker and consulting honoraria from Akcea, Alnylam and Pfizer, and travel grants from Kedrion, Alnylam and CSL Behring. Davide Pareyson reports financial grants (honoraria and speaking) from Alnylam, Akcea, Pfizer, and Inflectis, and travel grants from Kedrion and Pfizer. Silvia Fenu received financial grants (honoraria and speaking) from Alnylam, Akcea, and Pfizer and travel grants from Alnylam and Akcea. Luca Gentile is sub-investigator in clinical trials of Alnylam, Ionis, Takeda and reports travel grants from Kedrion and CSL Behring financial grants (consulting and speaking) from Pfizer. Funding Information: Open access funding provided by Universit{\`a} degli Studi di Padova within the CRUI-CARE Agreement. The present study was supported by an Investigator-Initiated Research to Azienda Ospedale Universit{\`a} of Padova from Pfizer Inc. Pfizer Inc had no role in the study design, data analysis, and results interpretation of the present study. Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

doi = "10.1007/s00415-021-10754-9",

language = "English",

journal = "Journal of Neurology",

issn = "0340-5354",

publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",

}

TY - JOUR

T1 - Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis

AU - Salvalaggio, Alessandro

AU - Coraci, Daniele

AU - Obici, Laura

AU - Cacciavillani, Mario

AU - Luigetti, Marco

AU - Mazzeo, Anna

AU - Pastorelli, Francesca

AU - Grandis, Marina

AU - Cavallaro, Tiziana

AU - Bisogni, Giulia

AU - Lozza, Alessandro

AU - Gemelli, Chiara

AU - Gentile, Luca

AU - Russo, Massimo

AU - Ermani, Mario

AU - Fabrizi, Gian Maria

AU - Plasmati, Rosaria

AU - De Napoli, Federica

AU - Campagnolo, Marta

AU - Castellani, Francesca

AU - Salvi, Fabrizio

AU - Fenu, Silvia

AU - Devigili, Grazia

AU - Pareyson, Davide

AU - Gasparotti, Roberto

AU - Rapezzi, Claudio

AU - Martinoli, Carlo

AU - Padua, Luca

AU - Briani, Chiara

N1 - Funding Information: Alessandro Salvalaggio reports travel grants from Akcea, Alnylam and Pfizer and consulting honoraria from Alnylam. Laura Obici reports speaker and consulting honoraria from Akcea, Alnylam and Pfizer. Marco Luigetti reports financial grants (honoraria and speaking) from Akcea, Alnylam and Pfizer, and travel grants from Pfizer, Kedrion and Grifols. Gulia Bisogni reports financial grants (honoraria and speaking) from Alnylam and travel grants from Pfizer and Grifols. Gian Maria Fabrizi reports consulting honoraria from Akcea and Alnylam, and travel grants from Kedrion and Alnylam. Chiara Gemelli reports travel grants from Akcea and Pfizer. Carlo Martinoli reports financial relationships (consultant, speaker fees, adv board) with Pfizer, Novartis, Sobi, Takeda and Novonordisk. Chiara Briani reports speaker and consulting honoraria from Akcea, Alnylam and Pfizer, and travel grants from Kedrion, Alnylam and CSL Behring. Davide Pareyson reports financial grants (honoraria and speaking) from Alnylam, Akcea, Pfizer, and Inflectis, and travel grants from Kedrion and Pfizer. Silvia Fenu received financial grants (honoraria and speaking) from Alnylam, Akcea, and Pfizer and travel grants from Alnylam and Akcea. Luca Gentile is sub-investigator in clinical trials of Alnylam, Ionis, Takeda and reports travel grants from Kedrion and CSL Behring financial grants (consulting and speaking) from Pfizer. Funding Information: Open access funding provided by Università degli Studi di Padova within the CRUI-CARE Agreement. The present study was supported by an Investigator-Initiated Research to Azienda Ospedale Università of Padova from Pfizer Inc. Pfizer Inc had no role in the study design, data analysis, and results interpretation of the present study. Publisher Copyright: © 2021, The Author(s).

PY - 2021

Y1 - 2021

N2 - Axonal polyneuropathy is the main feature of hereditary transthyretin amyloidosis (ATTRv). Nerve morphological abnormalities have been reported, but longitudinal changes have never been assessed. We performed a prospective widespread nerve ultrasound evaluation and nerve cross-sectional area (CSA) was compared with baseline data in both ATTRv patients and pre-symptomatic carriers. Thirty-eight subjects were evaluated (mean follow-up 17.1 months), among them 21 had polyneuropathy while 17 were pre-symptomatic carriers. CSA significantly increased at brachial plexus in both groups (p = 0.008 and p = 0.012) pointing to progressive brachial plexus enlargement as a longitudinal biomarker of both disease progression and disease occurrence in pre-symptomatic carriers.

AB - Axonal polyneuropathy is the main feature of hereditary transthyretin amyloidosis (ATTRv). Nerve morphological abnormalities have been reported, but longitudinal changes have never been assessed. We performed a prospective widespread nerve ultrasound evaluation and nerve cross-sectional area (CSA) was compared with baseline data in both ATTRv patients and pre-symptomatic carriers. Thirty-eight subjects were evaluated (mean follow-up 17.1 months), among them 21 had polyneuropathy while 17 were pre-symptomatic carriers. CSA significantly increased at brachial plexus in both groups (p = 0.008 and p = 0.012) pointing to progressive brachial plexus enlargement as a longitudinal biomarker of both disease progression and disease occurrence in pre-symptomatic carriers.

KW - Amyloidosis

KW - Brachial plexus

KW - Peripheral nerves

KW - Transthyretin

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=85112798994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85112798994&partnerID=8YFLogxK

U2 - 10.1007/s00415-021-10754-9

DO - 10.1007/s00415-021-10754-9

M3 - Article

AN - SCOPUS:85112798994

SN - 0340-5354

JO - Journal of Neurology

JF - Journal of Neurology

ER -

Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this